PDS Biotechnology Corp financial data

Symbol
PDSB on Nasdaq
Location
Princeton, NJ
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 13 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 248% % -35%
Debt-to-equity 151% % 40%
Return On Equity -209% % -50%
Return On Assets -83% % -24%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 48,980,307 shares 31%
Common Stock, Shares, Outstanding 47,705,442 shares 30%
Entity Public Float $103,716,155 USD -30%
Common Stock, Value, Issued $15,744 USD 30%
Weighted Average Number of Shares Outstanding, Basic 46,869,531 shares 27%
Weighted Average Number of Shares Outstanding, Diluted 46,869,531 shares 27%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $19,150,068 USD -25%
General and Administrative Expense $13,079,753 USD -5.7%
Operating Income (Loss) $32,229,821 USD 18%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $36,054,758 USD 16%
Income Tax Expense (Benefit) $269,820 USD
Net Income (Loss) Attributable to Parent $34,884,938 USD 14%
Earnings Per Share, Basic 0 USD/shares 30%
Earnings Per Share, Diluted 0 USD/shares 30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $26,198,652 USD -47%
Assets, Current $27,892,910 USD -46%
Property, Plant and Equipment, Net $125,643 USD -15%
Assets $34,705,801 USD -34%
Accounts Payable, Current $5,180,928 USD 298%
Accrued Liabilities, Current $2,104,390 USD -53%
Liabilities, Current $13,329,460 USD -27%
Liabilities $25,252,291 USD -17%
Retained Earnings (Accumulated Deficit) $209,043,585 USD -20%
Stockholders' Equity Attributable to Parent $9,453,510 USD -57%
Liabilities and Equity $34,705,801 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,032,256 USD 9.1%
Net Cash Provided by (Used in) Financing Activities $7,321,339 USD -63%
Common Stock, Shares Authorized 150,000,000 shares 0%
Common Stock, Shares, Issued 47,705,442 shares 30%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $26,198,652 USD -47%
Interest Paid, Excluding Capitalized Interest, Operating Activities $693,989 USD -41%
Deferred Tax Assets, Valuation Allowance $64,655,056 USD 14%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross $64,701,679 USD 14%
Depreciation $5,459 USD 15%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $34,884,938 USD 14%
Property, Plant and Equipment, Gross $295,911 USD 11%
Current Income Tax Expense (Benefit) $0 USD
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $0 USD -100%
Additional Paid in Capital $218,481,351 USD 11%
Deferred Tax Assets, Net of Valuation Allowance $46,623 USD -18%
Share-based Payment Arrangement, Expense $4,592,584 USD -30%
Interest Expense $4,413,822 USD 93%